The semi-annual reports of a number of multinational pharmaceutical companies disclose that these 10 drugs are the best sellers

The world's best-selling drugs, the latest ranking announced

01

Top 10 best-selling drugs in the world

Recently, many multinational pharmaceutical companies have successively disclosed their financial reports for the first half of 2021, and the latest sales of best-selling drugs have been announced

Source: WeChat public account of "Kailai British Medicine News"

In general, among the top 10 best-selling drugs in the world, one product is more than US$10 billion-Pfizer/BioNtech’s BTN162b2.

It can be seen that the sales of two drugs for the treatment of new coronary pneumonia surged in the first half of 2021-Pfizer/BioNtech's BTN162b2 sales in the first half of 2021 were 11.

Let's take a look at the top three drugs in terms of sales volume

02

New crown pneumonia drugs bring a surge in the performance of pharmaceutical companies

Pfizer announced its second quarter financial report for the second quarter of 2021.

In the first quarter of 2021, its total revenue reached US$14.

It is worth noting that Pfizer has publicly stated that it is currently negotiating the supply of the new crown vaccine with many governments.

Previous studies have shown that because BNT162b2 can provide high-efficiency protection for people of different ages and comorbidities, with an efficiency of 95%, it may become the first approved mRNA vaccine in China

Moderna's 2021 second-quarter performance report shows that the number of mRNA-1273 new crown vaccines sold reached 199 million doses, and sales reached 4.

On December 18, 2020, the FDA announced the approval of the emergency use authorization of Moderna's new crown vaccine mRNA-1273, and said that the emergency authorization vaccine is suitable for people 18 years and older

Judging from the overall sales performance, the performance of the two types of drugs used to treat new coronary pneumonia have both increased significantly this year

According to CCTV News, on July 18, the latest batch of approximately 860,000 doses of "Fobitai" vaccine has arrived in Hong Kong

Fosun Pharma’s financial report for the first quarter of 2021 showed that revenue increased by 37% year-on-year, and attributable net profit increased by 46.

Guotai Junan Securities once pointed out that the new crown vaccine has entered a performance cash-out period

03

Adalimumab still leads the way

From the perspective of overall sales, Adalimumab's global leadership is still unshakable

According to the "New Drug Frontier" WeChat official account, statistics show that from the approval of listing in 2003 to the end of June 2020, Xiu Meile has brought AbbVie a total of 165.

Earlier industry analysts pointed out that the excellent results of Humira are inseparable from AbbVie’s dual price strategy and resolutely defending its patent rights in the United States to prevent the launch of adalimumab biosimilars
.

It is worth noting that in 2018, Humira lost patent protection in Europe, and at least 6 biosimilar drugs were approved for marketing.
In addition, the patent for this heavy variety in the United States will expire in 2023, and there will be at least 9 models by then.
Biosimilar drugs enter the U.
S.
market
.

04

Significant increase in K drug

On July 29, Merck announced its financial report for the second quarter of 2021.
The total revenue for the first half of the year was US$22.
029 billion, a year-on-year increase of 12%
.
Revenue in the second quarter was approximately US$11.
402 billion, an increase of 22%
.

Public information shows that in 2020, Keytruda's global sales will reach 14.
380 billion U.
S.
dollars
.
In the first half of this year, K drug sales revenue was US$8.
078 billion, an increase of 23% over the same period last year
.

It is understood that this large variety has achieved rapid growth since its entry into the market in 2014.
In 2018, it ranked sixth in the world's best-selling drugs.
By 2019, it has jumped to second place, and it is expected to be second in 2020.
However, the distance with adalimumab has been continuously reduced
.

Informa believes that by 2023, K medicine will replace Xiu Mei Le as the global medicine king
.
Evaluate analysts also predict that Merck’s PD-1—K drug will replace AbbVie’s Humira and become the world’s best-selling drug
.

In the battle of "O, K" drugs, which is widely concerned in the industry, the sales of "O drugs" are obviously somewhat unsatisfactory.
Its global sales in 2020 are 7.
8 billion U.
S.
dollars, and there has been a negative growth
.

On the whole, the sales data ranking in the first half of 2021 has not changed significantly, but the drug for new coronary pneumonia has become the fastest attracting field
.
After the epidemic, we will wait and see who will continue to occupy the top position in drug sales
.